FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:70 January 6, 1994 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Olive, D. L.

To the Editor: I was dismayed by the minimal discussion of potential side effects of therapy in the recent review article on endometriosis by Olive and Schwartz (June 17 issue)¹. Although short-term use of gonadotropin-releasing hormone (GnRH) agonists is associated with a reversible decline in bone mineral density,² long-term therapy could lead to a sustained loss of bone. Low bone density is one of the major risk factors for osteoporosis, a disease that affects many women at great expense to society in terms of medical costs and decreased quality of life^3,4. Treatment of endometriosis with GnRH agonists has . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.